Next Article in Journal
A Lineage of Begomoviruses Encode Rep and AC4 Proteins of Enigmatic Ancestry: Hints on the Evolution of Geminiviruses in the New World
Next Article in Special Issue
Wild Rats, Laboratory Rats, Pet Rats: Global Seoul Hantavirus Disease Revisited
Previous Article in Journal
Effects of Arbovirus Multi-Host Life Cycles on Dinucleotide and Codon Usage Patterns
Previous Article in Special Issue
Current Situation and Perspectives on Hantaviruses in Mexico
Article Menu

Export Article

Open AccessArticle

Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses

1
Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E3R2, Canada
2
Department of Medical Microbiology, University of Manitoba, Winnipeg, MB R3E0J9, Canada
3
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
*
Author to whom correspondence should be addressed.
Authors contributed equally.
Viruses 2019, 11(7), 645; https://doi.org/10.3390/v11070645
Received: 6 May 2019 / Revised: 24 June 2019 / Accepted: 12 July 2019 / Published: 13 July 2019
(This article belongs to the Special Issue Hantaviruses)
  |  
PDF [2653 KB, uploaded 13 July 2019]
  |  

Abstract

Andes virus (ANDV) and Sin Nombre virus (SNV) are the main causative agents responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas. HCPS is a severe respiratory disease with a high fatality rate for which there are no approved therapeutics or vaccines available. Some vaccine approaches for HCPS have been tested in preclinical models, but none have been tested in infectious models in regard to their ability to protect against multiple species of HCPS-causing viruses. Here, we utilize recombinant vesicular stomatitis virus-based (VSV) vaccines for Andes virus (ANDV) and Sin Nombre virus (SNV) and assess their ability to provide cross-protection in infectious challenge models. We show that, while both rVSVΔG/ANDVGPC and rVSVΔG/SNVGPC display attenuated growth as compared to wild type VSV, each vaccine is able to induce a cross-reactive antibody response. Both vaccines protected against both homologous and heterologous challenge with ANDV and SNV and prevented HCPS in a lethal ANDV challenge model. This study provides evidence that the development of a single vaccine against HCPS-causing hantaviruses could provide protection against multiple agents. View Full-Text
Keywords: Hantavirus; prophylactic immunization; vaccine; vaccination; hantavirus cardiopulmonary syndrome; Andes virus; Sin Nombre virus Hantavirus; prophylactic immunization; vaccine; vaccination; hantavirus cardiopulmonary syndrome; Andes virus; Sin Nombre virus
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Warner, B.M.; Stein, D.R.; Jangra, R.K.; Slough, M.M.; Sroga, P.; Sloan, A.; Frost, K.L.; Booth, S.; Chandran, K.; Safronetz, D. Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses. Viruses 2019, 11, 645.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top